Virtual lab model for the generation of novel natural product derived therapeutics

迫切需要新的疗法来解决对人类健康的一些威胁，包括耐多药细菌和癌症。尽管英国开发的许多前景看好的生物技术为解决这些关键问题带来了巨大的希望，但很少有生物技术公司取得商业成功。Asidopl Ltd正在追求一种创新的虚拟公司模式，以利用现有的学术和商业能力，将合成生物学与合成化学结合起来，开发新的疗法。这种商业模式旨在减少开发新的专利保护疗法的时间和成本。该项目将允许进一步开发和评估Asidophl的商业模式，并与竞争对手公司使用的模式进行比较。

There exists a pressing need for new therapeutics to solve a number of threats to human health, including multidrug resistant bacteria and cancer. Although a number of promising biotechnologies developed in the UK hold great promise for solving these critical problems, few biotechnology companies achieve commercial success. Acidophil Ltd is pursuing an innovative virtual company model to exploit existing academic and commercial capabilities to combine synthetic biology with synthetic chemistry for the development of novel therapeutics. This business model is aimed towards decreasing the time and cost of developing novel patent protected therapeutics. The project will allow for further development and evaluation of Acidophil’s business model and a comparison to the models used by competing companies.